Table 3.

HRs of esophageal adenocarcinoma and the precursor lesions by serum IGF-I, IGFBP-3, and their ratios and frequency distribution (%) among persons with Barrett's esophagus

≤Median>MedianPtrend*
IGF-I
    Tetraploidy
        Yes (n = 42)54.845.2
        No (n = 267)49.850.2
    HR1.01.1 (0.6-2.3)0.62
    Aneuploidy
        Yes (n = 35)45.754.3
        No (n = 274)51.148.9
    HR1.00.9 (0.4-1.9)0.74
    Cancer
        Yes (n = 38)42.157.9
        No (n = 306)51.049.0
    HR1.01.3 (0.6-2.8)0.32
IGFBP-3§
    Tetraploidy
        Yes (n = 42)54.845.2
        No (n = 267)50.649.4
    HR1.00.91 (0.5-1.9)0.93
    Aneuploidy
        Yes (n = 35)31.468.6
        No (n = 274)51.548.5
    HR1.02.7 (1.2-6.0)0.02
    Cancer
        Yes (n = 38)42.157.9
        No (n = 306)51.049.0
    HR1.01.3 (0.6-2.8)0.61
IGF-I/IGFBP-3
    Tetraploidy
        Yes (n = 42)59.540.5
        No (n = 267)52.447.6
    HR1.01.0 (0.5-2.9)0.60
    Aneuploidy
        Yes (n = 35)54.345.7
        No (n = 274)52.247.8
    HR1.01.0 (0.7-1.4)0.10
    Cancer
        Yes (n = 38)39.560.5
        No (n = 306)53.346.7
    HR1.01.8 (0.9-359)0.10
  • * Ptrend values are based on quartile variables.

  • IGF-I median (ng/mL), 186.159, additional adjustment for IGFBP-3 levels.

  • Adjusted for gender, smoking status (current, former, or nonsmoker), quartiles of age, and waist/hip ratios.

  • § IGFBP-3 median (ng/mL), 3,634.9, additional adjustment for IGF-I levels.

  • IGF-I/IGFBP-3 (molar ratio) median, 0.1909.